What is Leerink Partnrs' Estimate for AC Immune Q3 Earnings?

Key Points

• Leerink Partnrs has raised its Q3 2025 earnings per share estimate for AC Immune from ($0.26) to ($0.25).
• AC Immune reported a quarterly loss of ($0.25) per share, which missed the consensus estimate of ($0.20) by ($0.05).
• The company has several upcoming earnings estimates, including a projected full-year loss of ($0.99) for FY2025 and earnings of $0.06 for FY2028.

AC Immune (NASDAQ:ACIU - Free Report) - Investment analysts at Leerink Partnrs boosted their Q3 2025 EPS estimates for shares of AC Immune in a research note issued on Tuesday, August 5th. Leerink Partnrs analyst M. Goodman now expects that the company will earn ($0.25) per share for the quarter, up from their previous forecast of ($0.26). The consensus estimate for AC Immune's current full-year earnings is ($0.62) per share. Leerink Partnrs also issued estimates for AC Immune's Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($0.99) EPS, FY2026 earnings at ($0.68) EPS and FY2028 earnings at $0.06 EPS.

AC Immune (NASDAQ:ACIU - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.05). AC Immune had a negative net margin of 174.94% and a negative return on equity of 49.35%. The firm had revenue of $1.65 million during the quarter, compared to analysts' expectations of $1.98 million.

Several other analysts have also recently weighed in on ACIU. HC Wainwright dropped their price target on shares of AC Immune from $16.00 to $12.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Wall Street Zen raised shares of AC Immune from a "hold" rating to a "buy" rating in a research report on Tuesday, May 13th.

AC Immune Stock Up 2.9%

Shares of AC Immune stock traded up $0.06 during mid-day trading on Friday, hitting $2.14. The stock had a trading volume of 97,918 shares, compared to its average volume of 163,494. The firm has a 50-day moving average of $2.07 and a two-hundred day moving average of $2.06. AC Immune has a 12-month low of $1.43 and a 12-month high of $3.98. The firm has a market cap of $214.88 million, a P/E ratio of -3.69 and a beta of 1.65.

Hedge Funds Weigh In On AC Immune

Hedge funds have recently made changes to their positions in the stock. Quinn Opportunity Partners LLC purchased a new position in shares of AC Immune during the 4th quarter worth approximately $27,000. Two Sigma Advisers LP purchased a new position in shares of AC Immune during the 4th quarter worth approximately $36,000. Boothbay Fund Management LLC purchased a new position in shares of AC Immune during the 4th quarter worth approximately $38,000. Banque Cantonale Vaudoise purchased a new position in shares of AC Immune during the 1st quarter worth approximately $50,000. Finally, Jane Street Group LLC acquired a new stake in AC Immune during the 4th quarter worth approximately $66,000. Hedge funds and other institutional investors own 51.36% of the company's stock.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.